expire program造句

• Renewal of the popular expiring program is part of the FDA overhaul package moving through Congress.
• It renews an expired program to give low tariffs to the Andean nations of Colombia, Peru, Ecuador and Bolivia.
• The legislation is critical for the drug industry because it renews an expiring program that has already cut drug review times dramatically.
• Additionally, the measure renews an expired program of low tariffs for selected products from the Andean nations of Colombia, Peru, Ecuador and Bolivia.
• The legislation is especially important for drug companies because it renews a popular expiring program that has already sped up reviews of new drugs dramatically.
• The legislation is important to drug companies because it renews and strengthens a popular expiring program that has already sped up reviews of new drugs dramatically.
• The legislation is also important for drug companies because it renews and strengthens a popular expiring program that has already sped up reviews of new drugs dramatically.
• The legislation is especially important for drug companies because it renews and strengthens a popular expiring program which has already sped up reviews of new drugs dramatically.
• The bill is critical for the drug industry because it renews an expiring program under which the industry pays fees in return for more staffing at the FDA and faster product reviews.
• That 10-year total reflects the bill s authorization of expiring programs through 2018 and an extension of those authorizations through 2023, consistent with the rules governing baseline projections that are specified in the Balanced Budget and Emergency Deficit Control Act of 1985.
• The bill is especially critical to the drug industry because it renews a expiring program known as the user fee act, which assesses fees on industry in return for more staffing and faster review times at the FDA . Both the FDA and industry representatives say the program is vital.
• The bill is critical for the drug industry because it renews an expiring program that speeds up drug reviews at the FDA . The medical device industry is also eager to see passage of the bill, saying it would improve procedures at the FDA and speed medical device approvals as well.